Altimmune Inc (ALT)
7.30
+0.11
(+1.53%)
USD |
NASDAQ |
May 03, 16:00
7.34
+0.04
(+0.55%)
After-Hours: 20:00
Altimmune Enterprise Value: 319.72M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 319.72M |
| May 02, 2024 | 311.92M |
| May 01, 2024 | 303.41M |
| April 30, 2024 | 266.55M |
| April 29, 2024 | 255.56M |
| April 26, 2024 | 316.88M |
| April 25, 2024 | 312.63M |
| April 24, 2024 | 304.12M |
| April 23, 2024 | 338.86M |
| April 22, 2024 | 331.77M |
| April 19, 2024 | 292.07M |
| April 18, 2024 | 290.65M |
| April 17, 2024 | 301.29M |
| April 16, 2024 | 335.32M |
| April 15, 2024 | 337.44M |
| April 12, 2024 | 368.64M |
| April 11, 2024 | 397.71M |
| April 10, 2024 | 370.06M |
| April 09, 2024 | 397.71M |
| April 08, 2024 | 412.59M |
| April 05, 2024 | 446.62M |
| April 04, 2024 | 433.15M |
| April 03, 2024 | 460.80M |
| April 02, 2024 | 465.41M |
| April 01, 2024 | 527.44M |
| Date | Value |
|---|---|
| March 28, 2024 | 523.90M |
| March 27, 2024 | 432.44M |
| March 26, 2024 | 415.43M |
| March 25, 2024 | 406.92M |
| March 22, 2024 | 445.91M |
| March 21, 2024 | 446.06M |
| March 20, 2024 | 462.31M |
| March 19, 2024 | 419.91M |
| March 18, 2024 | 443.94M |
| March 15, 2024 | 499.06M |
| March 14, 2024 | 510.73M |
| March 13, 2024 | 573.28M |
| March 12, 2024 | 570.45M |
| March 11, 2024 | 499.77M |
| March 08, 2024 | 536.52M |
| March 07, 2024 | 511.08M |
| March 06, 2024 | 607.20M |
| March 05, 2024 | 596.60M |
| March 04, 2024 | 583.17M |
| March 01, 2024 | 656.67M |
| February 29, 2024 | 657.38M |
| February 28, 2024 | 740.78M |
| February 27, 2024 | 778.24M |
| February 26, 2024 | 602.25M |
| February 23, 2024 | 452.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-33.51M
Minimum
Aug 25 2023
984.81M
Maximum
Jul 20 2020
211.09M
Average
166.92M
Median
Dec 30 2020
Enterprise Value Benchmarks
| Eli Lilly and Co | 722.23B |
| Amgen Inc | 221.30B |
| Pfizer Inc | 215.90B |
| Viking Therapeutics Inc | 7.524B |
| Precision BioSciences Inc | -21.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.64M |
| Revenue (Quarterly) | 0.037M |
| Total Expenses (Quarterly) | 21.24M |
| EPS Diluted (Quarterly) | -0.56 |
| Profit Margin (Quarterly) | -85.52K% |
| Earnings Yield | -22.88% |
| Normalized Earnings Yield | -22.88 |